ENTITY

Jiangsu Hengrui Pharmaceuticals (1276 HK)

316
Analysis
Health Care • China
Jiangsu Hengrui Pharmaceuticals is a global biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of innovative and high-quality drugs. The company focuses on therapeutic areas including oncology, metabolic and cardiovascular diseases, immunological and respiratory diseases, and neuroscience. It was founded in 1970 and is headquartered in Lianyungang, Jiangsu, China.
more
bullish•Muyuan Foods Co
•29 Jan 2026 18:51

Muyuan Foods H Share Listing (2714 HK): Valuation Insights

Muyuan Foods, the world’s largest pork company, has launched an H Share listing to raise US$1.4 billion. The proposed AH discount of 23.1% is...

Logo
340 Views
Share
bullish•Muyuan Foods Co
•29 Jan 2026 13:47

Aequitas: Muyuan Foods A/H Listing - Decent Pricing, Weak Momentum

Muyuan Foodstuff Co Ltd A (002714 CH) , a leader in the hog farming industry, aims to raise around US$1.4bn in its H-share listing. In this note,...

Logo
329 Views
Share
•27 Jan 2026 09:54

Aequitas: Wuxi Lead Intelligent Equipment A/H Listing - PHIP Updates and Thoughts on A/H Premium

Wuxi Lead Intelligent Equipmen (300450 CH), aims to raise up to US$700m in its H-share listing. In this note, we talk about the PHIP updates and...

Logo
307 Views
Share
•27 Jan 2026 07:30

Eastroc Beverage (9980 HK) IPO: Close to Fairly Priced

​Eastroc has solid growth with a 3-year EPS CAGR of 27.8%, supported by leadership in China's functional beverage market. Its IPO is fairly priced...

Logo
373 Views
Share
•26 Jan 2026 16:02

Eastroc Beverage H Share Listing (9980 HK): Valuation Insights

The proposed AH discount of 12.6% (based on the 23 January A Share price) is tight and will draw mixed views. Overall, I will tilt towards...

Logo
293 Views
Share
x